Results 41 to 50 of about 15,370 (316)

Antidrug Antibodies Against Immune Checkpoint Blockers: Impairment of Drug Efficacy or Indication of Immune Activation? [PDF]

Clinical Cancer Research, 2019
Abstract The generation of antibodies following exposure to therapeutic drugs has been widely studied, however in oncology, data in relation to their clinical relevance are limited. Antidrug antibodies (ADAs) can cause a decrease in the amount of drug available, resulting in some cases in decreased antitumor activity and a consequent ...
Diego Enrico, Angélo Paci, Nathalie Chaput, Eleni Karamouza, Benjamin Besse   +4 more
openalex   +3 more sources

Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy [PDF]

Science Advances, 2020
A prodrug hydrogelator serves as an effective immune booster for checkpoint blocker–based cancer immunotherapy.
Feihu Wang, Dongqing Xu, Hao Su, Weijie Zhang, Xuanrong Sun, Maya K. Monroe, Rami W. Chakroun, Zongyuan Wang, Wenbing Dai, Richard Oh, Han Wang, Qin Fan, Fengyi Wan, Honggang Cui   +13 more
openaire   +2 more sources

Intrinsic features of the cancer cell as drivers of immune checkpoint blockade response and refractoriness

Frontiers in Immunology, 2023
Immune checkpoint blockade represents the latest revolution in cancer treatment by substantially increasing patients’ lifetime and quality of life in multiple neoplastic pathologies.
Chiara Ursino, Cécile Mouric, Laurent Gros, Nathalie Bonnefoy, Julien Faget   +4 more
doaj   +1 more source

Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation. [PDF]

Cancer Cell, 2019
Although immune checkpoint blockers have yielded significant clinical benefits in patients with different malignancies, the efficacy of these therapies is still limited. Here, we show that disruption of transmembrane protein 176B (TMEM176B) contributes to CD8+ T cell-mediated tumor growth inhibition by unleashing inflammasome activation.
Segovia M, Russo S, Jeldres M, Mahmoud YD, Perez V, Duhalde M, Charnet P, Rousset M, Victoria S, Veigas F, Louvet C, Vanhove B, Floto RA, Anegon I, Cuturi MC, Girotti MR, Rabinovich GA, Hill M.   +17 more
europepmc   +8 more sources

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001. [PDF]

, 2016
Neuroendocrine tumors (NETs) are grouped together as a single class on the basis of histologic appearance, immunoreactivity for the neuroendocrine markers chromogranin A and synaptophysin, and potential secretion of hormones, neurotransmitters ...
Brzezniak, Christina, Cabrales, Pedro, Caroen, Scott, Carter, Corey A, Degesys, Aiste, Jenkins, John, Oronsky, Bryan, Peterson, P Gabriel, Quinn, Mary, Reid, Tony R, Schmitz, Bruno, Scicinski, Jan   +11 more
core   +4 more sources

The Interplay of Tumor Vessels and Immune Cells Affects Immunotherapy of Glioblastoma

Biomedicines, 2022
Immunotherapies with immune checkpoint inhibitors or adoptive cell transfer have become powerful tools to treat cancer. These treatments act via overcoming or alleviating tumor-induced immunosuppression, thereby enabling effective tumor clearance ...
Mitrajit Ghosh, Anna M. Lenkiewicz, Bozena Kaminska   +2 more
doaj   +1 more source

Human plasmacytoid dendritic cells and cutaneous melanoma [PDF]

, 2020
The prognosis of metastatic melanoma (MM) patients has remained poor for a long time. However, the recent introduction of effective target therapies (BRAF and MEK inhibitors for BRAFV600-mutated MM) and immunotherapies (anti-CTLA-4 and anti-PD-1) has ...
Bugatti, Mattia, Consoli, Francesca, Monti, Matilde, Vermi, William, Vescovi, Raffaella   +4 more
core   +2 more sources

Cardiotoxicity of immune checkpoint inhibitors [PDF]

, 2017
Cardiac toxicity after conventional antineoplastic drugs (eg, anthracyclines) has historically been a relevant issue. In addition, targeted therapies and biological molecules can also induce cardiotoxicity.
Allison, Atkins, Azuma, Azuma, Baban, Badros, Bellmunt, Bloom, Borghaei, Boussiotis, Boutros, Brahmer, Brahmer, Bretscher, Brunet, Buchbinder, Cardinale, Cardinale, Chen, Chen, Chen, Cooper, Corsello, Costa, Ding, Dong, Dong, Douglas, Dyck, Eigentler, Fehrenbacher, Francisco, Freeman, Freeman, Gagliani, Gangadhar, Garon, Gay, Geisler, Gibson, Goodman, Gordon, Grabie, Hamanishi, Hamid, Hamo, Han, Hathcock, Heinzerling, Herbst, Herbst, Hodi, Hofmann, Huang, Hurst, Jain, Johnson, Johnson, Johnston, Keir, Khan, Koelzer, Lacouture, Larkin, Lasaro, Latchman, Le Mercier, Le Mercier, Leach, Lesokhin, Lines, Linsley, Linsley, Lucas, Läubli, Mahoney, Martin, Matsuzaki, Menzies, Michot, Mohme, Moslehi, Moynihan, Naidoo, Nayak, Nghiem, Nguyen, Ni, Nishimura, Nishimura, Okamura, Okazaki, Okazaki, Pardoll, Peggs, Pitt, Postow, Powles, Prashanth, Ribas, Rittmeyer, Rizvi, Robert, Robert, Roth, Sakuishi, Semper, Sharma, Sharma, Sheppard, Sivan, Smyth, Spain, Stanietsky, Suter, Tadokoro, Tadokoro, Tarrio, Tivol, Tocchetti, Tocchetti, Topalian, Topalian, Tumeh, Voskens, Vétizou, Wang, Wang, Watanabe, Waterhouse, Weber, Westin, Wing, Wolchok, Woo, Yan, Yeh, Yokosuka, Yu, Yun, Zitvogel   +140 more
core   +1 more source

Immune checkpoint: The novel target for antitumor therapy

Genes and Diseases, 2021
Inhibitory checkpoint molecules include programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), cytotoxic T lymphocyte antigen-4 (CTLA-4), human endogenous retrovirus-H Long terminal repeat-associating 2 (HHLA2), B7 homolog 4 protein (B7 ...
Xianghu Jiang, Guohong Liu, Yirong Li, Yunbao Pan   +3 more
doaj   +1 more source

TAM receptor tyrosine kinases in cancer drug resistance [PDF]

, 2017
Receptor tyrosine kinases (RTK) are major regulators of key biological processes, including cell growth, survival, and differentiation, and were established early on as proto-oncogenes, with aberrant expression linked to tumor progression in many cancers.
Hafizi, Sassan, Vouri, Mikaella
core   +1 more source